Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus

Dong Hoon Chung, Sidath C. Kumarapperuma, Yanjie Sun, Qianjun Li, Yong Kyu Chu, Jeffrey B. Arterburn, William B. Parker, Jeffrey Smith, Kristin Spik, Harish N. Ramanathan, Connie S. Schmaljohn, Colleen Jonsson

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

There are no FDA approved drugs for the treatment of hemorrhagic fever with renal syndrome (HFRS), a serious human illnesses caused by hantaviruses. Clinical studies using ribavirin (RBV) to treat HFRS patients suggest that it provides an improved prognosis when given early in the course of disease. Given the unique antiviral activity of RBV and the lack of other lead scaffolds, we prepared a diverse series of 3-substituted 1,2,4-triazole-β-ribosides and identified one with antiviral activity, 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR). ETAR showed an EC50 value of 10 and 4.4 μM for Hantaan virus (HTNV) and Andes virus, respectively. ETAR had weak activity against Crimean Congo hemorrhagic fever virus, but had no activity against Rift Valley fever virus. Intraperitoneally delivered ETAR offered protection to suckling mice challenged with HTNV with a ∼25% survival at 12.5 and 25 mg/kg ETAR, and a MTD of 17.1 ± 0.7 days. ETAR was phosphorylated in Vero E6 cells to its 5′-triphosphate and reduced cellular GTP levels. In contrast to RBV, ETAR did not increase mutation frequency of the HTNV genome, which suggests it has a different mechanism of action than RBV. ETAR is an exciting and promising lead compound that will be elaborated in further synthetic investigations as a framework for the rational design of new antivirals for treatment of HFRS.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalAntiviral Research
Volume79
Issue number1
DOIs
StatePublished - Jul 1 2008

Fingerprint

Hantavirus
Ribavirin
Hantaan virus
Hemorrhagic Fever with Renal Syndrome
Antiviral Agents
Crimean-Congo hemorrhagic fever virus
Rift Valley fever virus
Vero Cells
Mutation Rate
Guanosine Triphosphate
Genome
Survival
1-ribofuranosyl-3-ethynyl-(1,2,4)triazole
In Vitro Techniques
Therapeutics
Pharmaceutical Preparations
Lead

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

Cite this

Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. / Chung, Dong Hoon; Kumarapperuma, Sidath C.; Sun, Yanjie; Li, Qianjun; Chu, Yong Kyu; Arterburn, Jeffrey B.; Parker, William B.; Smith, Jeffrey; Spik, Kristin; Ramanathan, Harish N.; Schmaljohn, Connie S.; Jonsson, Colleen.

In: Antiviral Research, Vol. 79, No. 1, 01.07.2008, p. 19-27.

Research output: Contribution to journalArticle

Chung, DH, Kumarapperuma, SC, Sun, Y, Li, Q, Chu, YK, Arterburn, JB, Parker, WB, Smith, J, Spik, K, Ramanathan, HN, Schmaljohn, CS & Jonsson, C 2008, 'Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus', Antiviral Research, vol. 79, no. 1, pp. 19-27. https://doi.org/10.1016/j.antiviral.2008.02.003
Chung, Dong Hoon ; Kumarapperuma, Sidath C. ; Sun, Yanjie ; Li, Qianjun ; Chu, Yong Kyu ; Arterburn, Jeffrey B. ; Parker, William B. ; Smith, Jeffrey ; Spik, Kristin ; Ramanathan, Harish N. ; Schmaljohn, Connie S. ; Jonsson, Colleen. / Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. In: Antiviral Research. 2008 ; Vol. 79, No. 1. pp. 19-27.
@article{fe1361919d584879a94d8d93e5c8254e,
title = "Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus",
abstract = "There are no FDA approved drugs for the treatment of hemorrhagic fever with renal syndrome (HFRS), a serious human illnesses caused by hantaviruses. Clinical studies using ribavirin (RBV) to treat HFRS patients suggest that it provides an improved prognosis when given early in the course of disease. Given the unique antiviral activity of RBV and the lack of other lead scaffolds, we prepared a diverse series of 3-substituted 1,2,4-triazole-β-ribosides and identified one with antiviral activity, 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR). ETAR showed an EC50 value of 10 and 4.4 μM for Hantaan virus (HTNV) and Andes virus, respectively. ETAR had weak activity against Crimean Congo hemorrhagic fever virus, but had no activity against Rift Valley fever virus. Intraperitoneally delivered ETAR offered protection to suckling mice challenged with HTNV with a ∼25{\%} survival at 12.5 and 25 mg/kg ETAR, and a MTD of 17.1 ± 0.7 days. ETAR was phosphorylated in Vero E6 cells to its 5′-triphosphate and reduced cellular GTP levels. In contrast to RBV, ETAR did not increase mutation frequency of the HTNV genome, which suggests it has a different mechanism of action than RBV. ETAR is an exciting and promising lead compound that will be elaborated in further synthetic investigations as a framework for the rational design of new antivirals for treatment of HFRS.",
author = "Chung, {Dong Hoon} and Kumarapperuma, {Sidath C.} and Yanjie Sun and Qianjun Li and Chu, {Yong Kyu} and Arterburn, {Jeffrey B.} and Parker, {William B.} and Jeffrey Smith and Kristin Spik and Ramanathan, {Harish N.} and Schmaljohn, {Connie S.} and Colleen Jonsson",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.antiviral.2008.02.003",
language = "English (US)",
volume = "79",
pages = "19--27",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus

AU - Chung, Dong Hoon

AU - Kumarapperuma, Sidath C.

AU - Sun, Yanjie

AU - Li, Qianjun

AU - Chu, Yong Kyu

AU - Arterburn, Jeffrey B.

AU - Parker, William B.

AU - Smith, Jeffrey

AU - Spik, Kristin

AU - Ramanathan, Harish N.

AU - Schmaljohn, Connie S.

AU - Jonsson, Colleen

PY - 2008/7/1

Y1 - 2008/7/1

N2 - There are no FDA approved drugs for the treatment of hemorrhagic fever with renal syndrome (HFRS), a serious human illnesses caused by hantaviruses. Clinical studies using ribavirin (RBV) to treat HFRS patients suggest that it provides an improved prognosis when given early in the course of disease. Given the unique antiviral activity of RBV and the lack of other lead scaffolds, we prepared a diverse series of 3-substituted 1,2,4-triazole-β-ribosides and identified one with antiviral activity, 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR). ETAR showed an EC50 value of 10 and 4.4 μM for Hantaan virus (HTNV) and Andes virus, respectively. ETAR had weak activity against Crimean Congo hemorrhagic fever virus, but had no activity against Rift Valley fever virus. Intraperitoneally delivered ETAR offered protection to suckling mice challenged with HTNV with a ∼25% survival at 12.5 and 25 mg/kg ETAR, and a MTD of 17.1 ± 0.7 days. ETAR was phosphorylated in Vero E6 cells to its 5′-triphosphate and reduced cellular GTP levels. In contrast to RBV, ETAR did not increase mutation frequency of the HTNV genome, which suggests it has a different mechanism of action than RBV. ETAR is an exciting and promising lead compound that will be elaborated in further synthetic investigations as a framework for the rational design of new antivirals for treatment of HFRS.

AB - There are no FDA approved drugs for the treatment of hemorrhagic fever with renal syndrome (HFRS), a serious human illnesses caused by hantaviruses. Clinical studies using ribavirin (RBV) to treat HFRS patients suggest that it provides an improved prognosis when given early in the course of disease. Given the unique antiviral activity of RBV and the lack of other lead scaffolds, we prepared a diverse series of 3-substituted 1,2,4-triazole-β-ribosides and identified one with antiviral activity, 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR). ETAR showed an EC50 value of 10 and 4.4 μM for Hantaan virus (HTNV) and Andes virus, respectively. ETAR had weak activity against Crimean Congo hemorrhagic fever virus, but had no activity against Rift Valley fever virus. Intraperitoneally delivered ETAR offered protection to suckling mice challenged with HTNV with a ∼25% survival at 12.5 and 25 mg/kg ETAR, and a MTD of 17.1 ± 0.7 days. ETAR was phosphorylated in Vero E6 cells to its 5′-triphosphate and reduced cellular GTP levels. In contrast to RBV, ETAR did not increase mutation frequency of the HTNV genome, which suggests it has a different mechanism of action than RBV. ETAR is an exciting and promising lead compound that will be elaborated in further synthetic investigations as a framework for the rational design of new antivirals for treatment of HFRS.

UR - http://www.scopus.com/inward/record.url?scp=43149119012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149119012&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2008.02.003

DO - 10.1016/j.antiviral.2008.02.003

M3 - Article

VL - 79

SP - 19

EP - 27

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -